Depsipeptides

"Depsipeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds consisting of chains of AMINO ACIDS alternating with CARBOXYLIC ACIDS via ester and amide linkages. They are commonly cyclized.

Descriptor ID	D047630
MeSH Number(s)	D04.345.566.297 D12.644.641.297
Concept/Terms	Depsipeptides Depsipeptides Cryptophycins Cryptophycins Depsipeptides, Cyclic Depsipeptides, Cyclic Cyclic Depsipeptides Cyclodepsipeptides

Below are MeSH descriptors whose meaning is more general than "Depsipeptides".

Chemicals and Drugs [D]
Polycyclic Compounds [D04]
Macrocyclic Compounds [D04.345]
Peptides, Cyclic [D04.345.566]
Depsipeptides [D04.345.566.297]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Peptides, Cyclic [D12.644.641]
Depsipeptides [D12.644.641.297]

Below are MeSH descriptors whose meaning is related to "Depsipeptides".

Below are MeSH descriptors whose meaning is more specific than "Depsipeptides".

Depsipeptides
Valinomycin

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Depsipeptides" by people in this website by year, and whether "Depsipeptides" was a major or minor topic of these publications.

Bar chart showing 21 publications over 15 distinct years, with a maximum of 3 publications in 2016 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2003	2	0	2
2005	1	0	1
2006	1	0	1
2008	0	1	1
2009	1	0	1
2012	1	0	1
2013	1	0	1
2014	1	0	1
2016	3	0	3
2017	1	2	3
2018	1	0	1
2019	1	1	2
2023	1	0	1
2024	1	0	1

Below are the most recent publications written about "Depsipeptides" by people in Profiles.

Ryu Tiger YK, Jain S, Barta SK, Tolu S, Estrella B, Sawas A, Lue JK, Francescone MM, Pro B, Amengual JE. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma. Leuk Lymphoma. 2024 06; 65(6):736-745.

View in: PubMed
Ruan J, Zain J, Palmer B, Jovanovic B, Mi X, Swaroop A, Winter JN, Gordon LI, Karmali R, Moreira J, Petrich AM, Pro B. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Adv. 2023 10 10; 7(19):5771-5779.

View in: PubMed
Vu K, Wu CH, Yang CY, Zhan A, Cavallone E, Berry W, Heeter P, Pincus L, Wieduwilt MJ, William BM, Andreadis C, Kaplan LK, McCormick F, Porcu P, Brammer JE, Ai WZ. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Clin Cancer Res. 2020 03 01; 26(5):1000-1008.

View in: PubMed
Griffith EC, Zhao Y, Singh AP, Conlon BP, Tangallapally R, Shadrick WR, Liu J, Wallace MJ, Yang L, Elmore JM, Li Y, Zheng Z, Miller DJ, Cheramie MN, Lee RB, LaFleur MD, Lewis K, Lee RE. Ureadepsipeptides as ClpP Activators. ACS Infect Dis. 2019 11 08; 5(11):1915-1925.

View in: PubMed
Lapadula D, Farias E, Randolph CE, Purwin TJ, McGrath D, Charpentier TH, Zhang L, Wu S, Terai M, Sato T, Tall GG, Zhou N, Wedegaertner PB, Aplin AE, Aguirre-Ghiso J, Benovic JL. Effects of Oncogenic Gaq and Ga11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res. 2019 04; 17(4):963-973.

View in: PubMed
Lee S, Levy RJ, Christian AJ, Hazen SL, Frick NE, Lai EK, Grau JB, Bavaria JE, Ferrari G. Calcification and Oxidative Modifications Are Associated With Progressive Bioprosthetic Heart Valve Dysfunction. J Am Heart Assoc. 2017 May 08; 6(5).

View in: PubMed
Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J, Balser B, Eisch R, Popplewell L, Prince HM, Allen SL, Piekarz R, Bates S. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma. 2017 Oct; 58(10):2335-2341.

View in: PubMed
Chua V, Lapadula D, Randolph C, Benovic JL, Wedegaertner PB, Aplin AE. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma. Mol Cancer Res. 2017 05; 15(5):501-506.

View in: PubMed
Foss F, Pro B, Miles Prince H, Sokol L, Caballero D, Horwitz S, Coiffier B. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Med. 2017 01; 6(1):36-44.

View in: PubMed
Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol. 2017 Dec; 35(4):914-917.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement